Comparative Analysis of Hta Decisions, Price and Reimbursement Level of Orphan Drugs In France and Italy

Comparative Analysis of Hta Decisions, Price and Reimbursement Level of Orphan Drugs In France and Italy

2014 Value in health

Korchagina, D. | Tavella, F. | Remuzat, C. | Kornfeld, A. | Toumi, M. | Volume: 17, Issue: 7, Pages: A539-A540, analysis, France, Italy, orphan drug, Price, Value,

While there exist a number of incentives to stimulate research and development of orphan drugs (OD), the Health Technology Assessment (HTA) agencies do not offer specific path for OD in most countries where it is left to payer value judgement. This leads to a high inequity in patient access to OD. The study aims at comparing the HTA decisions, price and reimbursement level of OD in France and Italy.

https://www.doi.org/10.1016/j.jval.2014.08.1732; 10.1016/j.jval.2014.08.1732